How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,624 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

14601. Association of three systemic lupus erythematosus susceptibility factors, PD-1.3A, C4AQ0, and low levels of mannan-binding lectin, with autoimmune manifestations in icelandic multicase systemic lupus erythematosus families. (Abstract)

Association of three systemic lupus erythematosus susceptibility factors, PD-1.3A, C4AQ0, and low levels of mannan-binding lectin, with autoimmune manifestations in icelandic multicase systemic lupus erythematosus families. To study autoimmune diseases and autoantibodies in Icelandic multicase systemic lupus erythematosus (SLE) families and to determine the association of 3 SLE susceptibility factors, PD-1.3A, C4AQ0, and low levels of mannan-binding lectin (MBL), with autoimmune disease

2008 Arthritis and Rheumatism

14602. Juvenile onset systemic lupus erythematosus: different clinical and serological pattern compared to adult onset systemic lupus erythematosus. (Abstract)

Juvenile onset systemic lupus erythematosus: different clinical and serological pattern compared to adult onset systemic lupus erythematosus. To investigate differences in clinical signs and symptoms, and in antinuclear antibodies (ANA), between patients with juvenile-onset and adult-onset systemic lupus erythematosus (SLE).Clinical and serological data of 56 patients with juvenile-onset SLE were compared with data of 194 patients with adult-onset SLE. ANA were determined by line immunoassay

2008 Annals of the Rheumatic Diseases

14603. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. (Abstract)

Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Recent case-control studies show associations of the minor T allele (of the C1858T single-nucleotide polymorphism corresponding to the R620W amino acid substitution) of PTPN22 with multiple autoimmune diseases, including systemic lupus erythematosus (SLE). We (...) performed family-based association studies of this polymorphism in 4 independent cohorts containing SLE patients and their parents and/or other family members.A total of 2,689 individuals from 902 independent Caucasian families with SLE were genotyped using polymerase chain reaction pyrosequencing (cohorts 1 and 2) and the Sequenom MassArray system (cohorts 3 and 4). The transmission disequilibrium test (TDT) and the pedigree disequilibrium test (PDT) were conducted to assess the evidence

2005 Arthritis and Rheumatism

14604. Absence of an association between antibodies to retroviral proteins and anticardiolipin antibody and/or lupus anticoagulant in systemic lupus erythematosus. Full Text available with Trip Pro

Absence of an association between antibodies to retroviral proteins and anticardiolipin antibody and/or lupus anticoagulant in systemic lupus erythematosus. 8017993 1994 07 28 2018 11 13 0003-4967 53 5 1994 May Annals of the rheumatic diseases Ann. Rheum. Dis. Absence of an association between antibodies to retroviral proteins and anticardiolipin antibody and/or lupus anticoagulant in systemic lupus erythematosus. 352-3 Matsuda J J Gotoh M M Gohchi K K Tsukamoto M M Saitoh N N eng Letter (...) England Ann Rheum Dis 0372355 0003-4967 0 Antibodies, Anticardiolipin 0 Antibodies, Viral 0 HIV Antibodies 0 HTLV-I Antibodies 0 Lupus Coagulation Inhibitor 0 Retroviridae Proteins IM X Adult Antibodies, Anticardiolipin blood Antibodies, Viral blood Female HIV Antibodies blood HTLV-I Antibodies blood Humans Lupus Coagulation Inhibitor analysis Lupus Erythematosus, Systemic immunology Male Retroviridae Proteins immunology 1994 5 1 1994 5 1 0 1 1994 5 1 0 0 ppublish 8017993 PMC1005341 Med Microbiol

1994 Annals of the Rheumatic Diseases

14605. Gangrene developing after minor surgery in a patient with undiagnosed systemic lupus erythematosus and lupus anticoagulant. Full Text available with Trip Pro

Gangrene developing after minor surgery in a patient with undiagnosed systemic lupus erythematosus and lupus anticoagulant. We report a case of progressive peripheral ischaemia and gangrene as a presenting feature of systemic lupus erythematosus. It developed in a previously asymptomatic 40-year-old woman following minor surgery to her toe. Eventually she required a below-knee amputation and despite systemic corticosteroids continued to deteriorate, presenting later with signs of systemic (...) intravascular thromboses. Histopathology and immunofluorescence on vessels repeatedly failed to demonstrate any evidence for vasculitis. A full coagulation screen confirmed the presence of 'lupus' anticoagulant. A plasma exchange was performed to remove circulating immunoglobins and she made a rapid and sustained recovery. Peripheral gangrene has not previously been described in association with lupus anticoagulant. We would suggest that in all cases of systemic thrombosis or unexplained peripheral vascular

1983 Annals of the Rheumatic Diseases

14606. Systemic lupus erythematosus in child with autoimmune thrombocytopenic purpura and circulating lupus anticoagulant. Full Text available with Trip Pro

Systemic lupus erythematosus in child with autoimmune thrombocytopenic purpura and circulating lupus anticoagulant. 3106634 1987 05 29 2018 11 13 0141-0768 80 3 1987 Mar Journal of the Royal Society of Medicine J R Soc Med Systemic lupus erythematosus in child with autoimmune thrombocytopenic purpura and circulating lupus anticoagulant. 186 Davies S M SM Dunger D B DB eng Case Reports Journal Article England J R Soc Med 7802879 0141-0768 0 Blood Coagulation Factors 0 Lupus Coagulation Inhibitor (...) 9PHQ9Y1OLM Prednisolone IM Adolescent Autoimmune Diseases blood etiology Blood Coagulation Factors blood immunology Female Humans Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic blood complications Platelet Count drug effects Prednisolone therapeutic use Purpura, Thrombocytopenic blood etiology 1987 3 1 1987 3 1 0 1 1987 3 1 0 0 ppublish 3106634 PMC1290730 J Pediatr. 1980 Mar;96(3 Pt 1):439-41 7359239 Lancet. 1981 Jun 6;1(8232):1228-31 6112565 Lancet. 1983 Nov 26;2(8361):1211-4 6139567 Am J Dis

1987 Journal of the Royal Society of Medicine

14607. Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. Full Text available with Trip Pro

Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant. To elucidate the mechanism of vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant changes in factors associated with haemostasis were investigated. The lupus anticoagulant was associated with an increased incidence of thrombosis, particularly cerebral thrombosis. Concentrations of fibrinopeptide A and fibrinopeptide B beta (...) 15-42 were significantly raised in the plasma of patients with systemic lupus erythematosus and the anticoagulant compared with concentrations in patients without the lupus anticoagulant. The tendency towards formation of thrombosis was not found in all lupus patients with the anticoagulant, however. Concentrations of thromboxane B2 were remarkably raised in the plasma of the two patients with the lupus anticoagulant who had recently had thrombosis. Concentrations of 6-keto-prostaglandin F1 alpha

1991 Annals of the Rheumatic Diseases

14608. Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus. Full Text available with Trip Pro

Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus. The significance of anticardiolipin antibodies and the lupus anticoagulant was studied in 58 consecutive patients with systemic lupus erythematosus. On 85 occasions serum IgG and IgM anticardiolipin antibodies were measured by an enzyme linked immunosorbent assay (ELISA), and simultaneous plasma samples tested for lupus anticoagulant activity. The most significant association (...) and lupus anticoagulant negative, of whom one had thrombocytopenia but none had thrombosis. The presence of a lupus anticoagulant in anticardiolipin antibody positive patients increases specificity for certain adverse clinical events.

1991 Annals of the Rheumatic Diseases

14609. Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus. Full Text available with Trip Pro

Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus. To examine the sensitivity and specificity to past thrombotic events of four different coagulation tests, which screen for lupus anticoagulant (LA), and of anticardiolipin antibodies in patients with systemic lupus erythematosus.Fifty three consecutive patients with systemic lupus erythematosus were studied of whom three males and 21 females, aged 21-60 (...) than 0.001). No significant differences in specificity were found among aPTT (100%), dRVVT (93%), KCT (93%) and dilute aPTT (86.2%); but aPTT and dRVVT were significantly more specific (p less than 0.01, p less than 0.05, respectively) than anticardiolipin antibodies.The study shows a strong association between lupus anticoagulant and thrombosis when a very sensitive test such as the dilute aPTT is used. The combination of this assay with a very specific test such as dRVVT might enable patients

1992 Journal of Clinical Pathology

14610. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Full Text available with Trip Pro

Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Fluctuations of lupus anticoagulant activity and anticardiolipin antibody titres were studied in 53 patients with systemic lupus erythematosus (SLE). The median study time was 26 months with a median number of 12 samples. Lupus anticoagulant was measured by the kaolin clotting time (KCT) and dilute Russell viper venom time (dRVVT) assays (...) patients. Whole group analysis showed that the KCT, dRVVT, and IgM anticardiolipin antibodies were not associated with disease activity, in contrast with IgG anticardiolipin antibodies. During treatment with prednisone normal KCT and dRVVT results were obtained more easily than normal anticardiolipin antibody levels. It is recommended that lupus patients should not be classified as antiphospholipid antibody positive or negative on the basis of only one sample.

1992 Annals of the Rheumatic Diseases

14611. Immunofluorescence microscopy of healthy skin from patients with systemic lupus erythematosus: more than just the lupus band. Full Text available with Trip Pro

Immunofluorescence microscopy of healthy skin from patients with systemic lupus erythematosus: more than just the lupus band. Many papers have been published on the lupus band in systemic lupus erythematosus (SLE), but little information exists on the possible diagnostic value of the lupus band and other microscopic immunofluorescence phenomena found in clinically normal skin of patients with SLE. In a study of 297 subjects (66 patients with SLE, 81 patients with other forms of LE, and 150 (...) patients with other systemic connective tissue disorders) it was found that: (a) granular deposits of IgA, IgG, and IgM in the basal membrane zone and in the deeper blood vessels were more common in patients with SLE than in the other two groups; (b) depending on the clinical differential diagnosis, IgA and IgG deposits at the epidermal basal membrane can be specific for SLE; (c) using logistic regression analysis sets of variables can be selected with a high potential to discriminate between SLE

1992 Annals of the Rheumatic Diseases

14612. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. (Abstract)

Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. The rarity with which therapy-free remission is achieved in patients with severe SLE demand the continued search for improved treatment strategies. Possibly, therapeutic results can be improved by means of a "synchronized" combination of plasmaphereses followed by pulse cyclophosphamide (Ctx). If the hypothesis is correct, that plasmapheresis (...) induces a compensatory "rebound" proliferation of pathogenic clones, then pulse Ctx applied immediately after plasmapheresis should attack these activated clones when they are most vulnerable and, ideally, eliminate them. Employing a strict variant of this strategy in a pilot study, treatment-free remission lasting now for up to 7 years were achievable in 8 of 14 SLE patients. The Lupus Plasmapheresis Study Group (LPSG) is currently conducting a randomized international multicenter trial comparing

1994 Annales de médecine interne Controlled trial quality: uncertain

14613. Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations. Full Text available with Trip Pro

Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations. The prevalence of lupus anticoagulant (LAC) and its relation with reported clinical associations has been determined in 55 patients with systemic lupus erythematosus (SLE) from northern India who were studied prospectively. Kaolin clotting time was used to screen for LAC, which was detected in seven (13%) of the patients. Significant associations were found between LAC and thrombotic events, onset

1990 Annals of the Rheumatic Diseases

14614. Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant. Full Text available with Trip Pro

Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant. A patient with systemic lupus erythematosus was first diagnosed after she had developed the Budd-Chiari syndrome. We believe that the Budd-Chiari syndrome was part of her tendency for thrombosis, induced by the presence of a lupus anticoagulant. The association between enhanced thrombosis and the lupus anticoagulant is discussed, and the need for prompt recognition

1986 Annals of the Rheumatic Diseases

14615. ABC of rheumatology. Systemic lupus erythematosus and lupus-like syndromes. Full Text available with Trip Pro

ABC of rheumatology. Systemic lupus erythematosus and lupus-like syndromes. 7767201 1995 07 03 2008 11 20 0959-8138 310 6989 1995 May 13 BMJ (Clinical research ed.) BMJ ABC of rheumatology. Systemic lupus erythematosus and lupus-like syndromes. 1257-61 Hay E M EM Staffordshire Rheumatology Centre, Stoke on Trent. Snaith M L ML eng Journal Article Review England BMJ 8900488 0959-8138 AIM IM BMJ. 1995 Jul 22;311(6999):264-5 7627077 Humans Lupus Erythematosus, Systemic diagnosis etiology therapy 0

1995 BMJ : British Medical Journal

14616. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus Full Text available with Trip Pro

Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus Although deforming arthropathy in systemic lupus erythematosus (SLE) is characterised by a number of manifestations, definitive criteria for the different forms have not yet been established. To define deforming arthropathy and its different types a study was undertaken of 176 SLE patients.Using as criterion any deviation from any of the metacarpus finger axes 17 patients (16 women, one man) were identified (...) with clinical deforming arthropathy. These patients were evaluated according to a standardised protocol that covered all known characteristics of deforming arthropathy. By means of "Jaccoud's arthropathy index" three different forms were identified.Three patients had an erosive form of deforming arthropathy (or rhupus hand) such as those seen in frank rheumatoid arthritis (RA), eight patients were identified as having Jaccoud's arthropathy (or lupus hand), and the remaining six patients had mild deforming

1998 Annals of the Rheumatic Diseases

14617. Mycobacteria, an environmental enhancer of lupus nephritis in a mouse model of systemic lupus erythematosus Full Text available with Trip Pro

Mycobacteria, an environmental enhancer of lupus nephritis in a mouse model of systemic lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of antibodies directed against self antigens. Immune complex glomerulonephritis (GN) is one of the most serious complications of this disorder and can lead to potentially fatal renal failure. The aetiology of SLE is complex and multifactorial, characterized by interacting (...) environmental and genetic factors. Here we examine the nature of the renal pathology in mycobacteria-treated non-obese diabetic (NOD) mice, in order to assess its suitability as a model for studying the aetiopathogenesis of, and possible treatment options for, lupus nephritis (LN) in humans. Both global and segmental proliferative lesions, characterized by increased mesangial matrix and cellularity, were demonstrated on light microscopy, and lesions varied in severity from very mild mesangiopathic GN

2003 Immunology

14618. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis) Full Text available with Trip Pro

Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis) To determine the causes of acute abdominal pain in systemic lupus erythematosus (SLE) and to compare the clinical and laboratory data, especially antiphospholipid antibodies and the SLE Disease Activity Index (SLEDAI), between lupus enteritis (gastrointestinal vasculitis) and acute abdominal pain without lupus enteritis in patients with SLE.A retrospective study was carried out for all (...) patients admitted with SLE from 1993 to March 2001. The SLEDAI and laboratory data were collected at the time of diagnosis of SLE and at the time of acute abdominal pain. Lupus enteritis (gastrointestinal vasculitis) was diagnosed by clinical investigation and abdominal computed tomographic findings.Chart review identified 175 patients (20 male, 155 female) who had been admitted with SLE. Of these patients, 38 (22%) presented with acute abdominal pain. Lupus enteritis was the most common cause of acute

2002 Annals of the Rheumatic Diseases

14619. Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus. (Abstract)

Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus. We describe 2 patients with systemic lupus erythematous whose widespread discoid lupus erythematosus was unresponsive to systemic steroids and antimalarial agents. They showed dramatic improvement to thalidomide at a dose of 300 mg/d, with maximum benefit achieved within 15 weeks of therapy. Dosages of 50 to 100 mg/d were effective in maintaining remission for 1 year. However

2003 Journal of American Academy of Dermatology

14620. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. (Abstract)

European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. To evaluate the European Consensus Lupus Activity Measurement (ECLAM) for responsiveness to change in disease activity when used in childhood-onset systemic lupus erythematosus (cSLE). To confirm the construct validity and to characterize the measurement properties of the ECLAM by assessing its ability to predict damage and steroid requirements.The disease (...) courses of 66 newly diagnosed cSLE patients were reviewed. The ECLAM and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) were scored for all clinic visits and hospitalizations. Damage was assessed at the end of the followup period using the Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index. Disease activity at the time of diagnosis, 6 months after diagnosis, at the time of first flare, and 6 months after first flare was used to estimate

2003 Arthritis and Rheumatism

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>